Gastrointestinal Drugs Market Report 2025 (Global Edition)

Global Gastrointestinal Drugs Market Report 2025 Market Size Split by Drug Class (Acid Neutralizers, , Antacids, H2 antagonists, Proton pump inhibitors, , Antidiarrheal and Laxatives, Antiemetic and ...

Gastrointestinal Drugs Market Report Description

We have various report editions of Gastrointestinal Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape: The Gastrointestinal Drugs market

Prominent industry players are making significant R&D investments to broaden their range of products, hence contributing to the further expansion of the Gastrointestinal Drugs market. To expand their influence, market players are also taking part in a range of strategic initiatives. Notable developments in the industry include the launch of new products, contracts, mergers and acquisitions, higher investments, and collaboration with other organizations. To grow and thrive in an increasingly cutthroat and dynamic market, the gastrointestinal pharmaceuticals sector needs to provide affordable products. 

For instance, in May 2023, Ironwood Pharmaceuticals, Inc., and VectivBio Holding AG, a clinical-stage biopharmaceutical company introducing novel, transformational therapies for severe rare GI conditions, entered into a definitive agreement for Ironwood to acquire the latter company for $17.00.

Source:(https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Enters-into-Definitive-Agreement-to-Acquire-VectivBio-a-Clinical-Stage-Biotech-Company-Pioneering-Novel-Treatments-for-Severe-Rare-Gastrointestinal-Diseases/default.aspx)
 

Top Companies Market Share in Gastrointestinal Drugs Industry: (In no particular order of Rank)

• Takeda Pharmaceuticals
• Allergan Plc
• Novo Nordisk A/S
• AstraZeneca Plc
• AbbVie Inc.
• Valeant Pharmaceuticals Inc.
• Johnson & Johnson
• Bayer AG
• Boehringer Ingelheim GmbH
• GlaxoSmithKline Plc.
• Janssen Biotech Inc.
• Sanofi
• Salix Pharmaceuticals
• Abbott
• Pfizer Inc.
• Cipla Inc.
• Biogen
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of Gastrointestinal Drugs market

Which Region Will Dominate the Market in 2024?

According to Cognitive Research, the North American region dominated the Gastrointestinal drugs market and accounted for the highest revenue of XX% in 2024 and it is projected that it will grow at a CAGR of XX% in the future. North America is anticipated to hold the highest market share due to factors like the rising prevalence of gastrointestinal illnesses, rising product releases, and expanding corporate activities. The primary driver of the market's growth is the rising prevalence of gastrointestinal disorders among the general public, including ulcerative colitis and others. 

For instance, in April 2022, As per Centers for Disease Control and Prevention, an estimated 3.1 million adults (1.3%) in the United States have been diagnosed with inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. It is a broad term that indicates chronic inflammation of the gastrointestinal tract.

For instance, an article released by the National Foundation for Infectious Diseases in July 2023 underscored the prevalence of Norovirus, also known as Norovirus or stomach flu, which accounted for 19 to 21 million incidents of vomiting and diarrhea in the United States during the year 2023. This resulted in 450,000 emergency room admissions and 109,000 hospitalizations. Notably, during the winter season in 2023, there was a notable increase in cases and outbreaks, peaking in March 2023, with elevated norovirus activity persisting well into late spring.

Source:(https://www.nfid.org/infectious-disease/norovirus/)

Which Region Is Expanding at The Fastest CAGR?

The Asia Pacific region's gastrointestinal drugs market is expected to experience the fastest growth rate with a CAGR of XX% during the forecast period. Asia's gastrointestinal drugs market is segmented based on region: China, India, the Republic of Korea, and the Rest of Asia. Japan accounts for the major share of the market owing to its well-developed technology and high healthcare expenditure. People in this region are more focused on health, which drives the growth of the market. China is the second largest market, followed by India. Owing to government support for research & development, well-developed healthcare infrastructure, and high healthcare expenditure drive the Chinese gastrointestinal drugs market. India is the fastest-growing gastrointestinal drug market across the region. The increasing need for better treatment methods rapidly changing the healthcare sector. Additionally, the presence of huge opportunities for the development of the market has boosted the market growth. India is experiencing a high demand for gastrointestinal disorder drugs. Major pharmaceutical drug manufacturers are using their technology and services to develop new drugs for gastrointestinal diseases to meet the growing demand. 

For instance, in September 2022, Takeda announced the national launch of the CDPATHTM program today, which included an innovative, validated personalized prognostic tool utilizing blood tests to assist in predicting the potential risk of developing serious complications related to Crohn’s disease within three years.

Source:(https://www.takeda.com/en-us/newsroom/news-releases/2022/takeda-launches-cdpath#:~:text=CAMBRIDGE%2C%20Massachusetts%2C%20September%2014%2C,developing%20serious%20Crohn's%20disease%2Drelated)
 

The current report Scope analyzes Gastrointestinal Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

Gastrointestinal Drugs Market Analysis

Segment Performance in The Gastrointestinal Drugs market

Drug Class Segment Analysis

Biologics dominate the gastrointestinal drugs market due to their targeted mechanism of action, which effectively addresses underlying inflammatory processes in conditions like Crohn's disease and ulcerative colitis. Their high efficacy and reduced side effects compared to traditional therapies make them preferred among patients and physicians alike. The segment demand is being driven by the high prescription rate for biologic and biosimilar preparations as well as the high efficacy of medications in treating gastrointestinal illnesses including Crohn's disease, ulcerative colitis, GERD, and others. Some common biologic preparations used to treat gastrointestinal disorders are adalimumab, certolizumab, infliximab, natalizumab, and others.

For instance, in December 2021, the U.S. FDA approved Yusimry, a biosimilar to adalimumab, developed by Coherus BioSciences. However, the prescription rate of aminosalicylates and proton pump inhibitors, among others, are also high for the treatment of gastrointestinal disorders.

Source:(https://investors.coherus.com/news-releases/news-release-details/coherus-announces-industry-wide-lowest-list-price-adalimumab)

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Gastrointestinal Drugs Industry. Request a Free Sample PDF!

Distribution Channel Segment Analysis

Retail pharmacies hold the largest market share. Retail pharmacies emerge as the primary distribution channel for gastrointestinal drugs due to their accessibility and convenience for patients. Most gastrointestinal conditions necessitate ongoing medication adherence and monitoring, making retail pharmacies the go-to destination for prescription refills and consultations with pharmacists. The market is expanding due to several factors, including the growing need for over-the-counter medications including antacids, anti-emetics, and laxative preparations, as well as unsanitary eating habits that frequently cause upset stomachs. Additionally, the availability of innovative medications and the growing acceptance and use of oral medications for the treatment of GI problems are fueling expansion. 

For instance, in March 2024 according to the Gastroenterology drug report The US Food and Drug Administration approved five new gastrointestinal targeted drugs in 2023, including for GERD, IBD, and colonoscopy prep. 

Source:(https://www.medcentral.com/gastroenterology/gastroenterology-drug-report-new-and-notable-approvals)

For instance, in May 2023 FDA approved Rinvoq (upadacitinib) for adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. Rinvoq is the first approved oral product available to treat moderately to severely active Crohn’s disease.

Source:(https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-oral-treatment-moderately-severely-active-crohns-disease)

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Gastrointestinal Drugs Route of Administration Segment Analysis

Route of Administration Segment Analysis

The Intravenous segment commands a significant market share in gastrointestinal drugs due to its ability to deliver potent medications directly into the bloodstream, ensuring rapid onset of action and precise dosing control. This route is often favored in acute gastrointestinal conditions such as severe diarrhea or bleeding, where oral administration may be impractical or ineffective. The high rate of acceptance of biological medications, in conjunction with their higher cost, greater bioavailability, quick beginning of action, and reduced likelihood of first-pass metabolism in the case of injectable pharmaceuticals. Additionally, the segment share has expanded due to the availability of several intravenous medications for the treatment of gastrointestinal disorders. For instance, top-selling products such as Tysabri, Entyvio, and Sandostatin are administered via the intravenous route.
 

• Oral
• Intravenous
• Rectal

Gastrointestinal Drugs Disorder Type Segment Analysis

Disorder Type Segment Analysis

Gastroesophageal Reflux Disease (GERD) holds the largest market share in gastrointestinal drugs due to its widespread prevalence and chronic nature. The rising prevalence of gastrointestinal reflux diseases and increasing awareness about GERD are fuelling the growth of this segment. The condition's symptoms, including heartburn and regurgitation, significantly impact patients' quality of life, driving demand for effective pharmacological management. Proton pump inhibitors (PPIs) and H2-receptor antagonists are commonly prescribed to alleviate symptoms and prevent complications, contributing to this segment's dominance.

For instance, in December 2023 as per an article published in Medical News Today, GERD is most common in Western countries, affecting an estimated 20% Trusted Source of the population in these regions. About 20% of Americans also have GERD, and it is the most common gastrointestinal condition diagnosed in the outpatient setting. About 60% of people who have GERD are women. Among people living with GERD, African Americans account for the second-largest group after people who are white.

Source:(https://www.medicalnewstoday.com/articles/146619)

• Gastroesophageal Reflux Disease
• Inflammatory Bowel Disease
• Irritable Bowel Syndrome

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion